Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06130566
Registration number
NCT06130566
Ethics application status
Date submitted
8/11/2023
Date registered
14/11/2023
Date last updated
31/05/2024
Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Query!
Scientific title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Query!
Secondary ID [1]
0
0
U1111-1275-9715
Query!
Secondary ID [2]
0
0
EFC17559
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
COAST 1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Dermatitis Atopic
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Amlitelimab
Treatment: Drugs - Placebo
Experimental: Amlitelimab dose 1 - Subcutaneous injection as per protocol
Experimental: Amlitelimab dose 2 - Subcutaneous injection as per protocol
Placebo Comparator: Placebo - Subcutaneous injection as per protocol
Treatment: Drugs: Amlitelimab
Injection solution SC injection
Treatment: Drugs: Placebo
Injection solution SC injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of =2 points at Week 24
Query!
Assessment method [1]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [1]
0
0
Week 24
Query!
Primary outcome [2]
0
0
EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24
Query!
Assessment method [2]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
Query!
Timepoint [2]
0
0
Week 24
Query!
Primary outcome [3]
0
0
US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of =2 points at Week 24
Query!
Assessment method [3]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [3]
0
0
Week 24
Query!
Secondary outcome [1]
0
0
Proportion of participants reaching EASI-75 at Week 24 (for US and US reference countries only)
Query!
Assessment method [1]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [2]
0
0
Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting)
Query!
Assessment method [2]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [2]
0
0
Baseline to Week 24
Query!
Secondary outcome [3]
0
0
Proportion of participants with =4-point reduction in weekly average of daily Peak Pruritus-Numerical Rating Scale (PP-NRS) from baseline in participants with baseline weekly average of daily PP-NRS =4
Query!
Assessment method [3]
0
0
The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Query!
Timepoint [3]
0
0
Baseline to Week 24
Query!
Secondary outcome [4]
0
0
Proportion of participants reaching EASI-75
Query!
Assessment method [4]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.
Query!
Timepoint [4]
0
0
Baseline to Week 20
Query!
Secondary outcome [5]
0
0
Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of =2 points
Query!
Assessment method [5]
0
0
The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).
Query!
Timepoint [5]
0
0
Baseline to Week 20
Query!
Secondary outcome [6]
0
0
Proportion of participants reaching EASI-90
Query!
Assessment method [6]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.
Query!
Timepoint [6]
0
0
Baseline to Week 24
Query!
Secondary outcome [7]
0
0
Proportion of participants reaching EASI-100
Query!
Assessment method [7]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.
Query!
Timepoint [7]
0
0
Baseline to Week 24
Query!
Secondary outcome [8]
0
0
Proportion of participants with PP-NRS 0 or 1
Query!
Assessment method [8]
0
0
The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Query!
Timepoint [8]
0
0
Baseline to Week 24
Query!
Secondary outcome [9]
0
0
Change in Dermatology Life Quality Index (DLQI) from baseline in participants with age =16 years old
Query!
Assessment method [9]
0
0
The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Query!
Timepoint [9]
0
0
Baseline to Week 24
Query!
Secondary outcome [10]
0
0
Proportion of participants with a reduction in DLQI =4 from baseline in participants with age =16 years old and with DLQI baseline =4
Query!
Assessment method [10]
0
0
The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Query!
Timepoint [10]
0
0
Baseline to Week 24
Query!
Secondary outcome [11]
0
0
Change in Children Dermatology Life Quality Index (CDLQI) from baseline in participants with age =12 to <16 years old
Query!
Assessment method [11]
0
0
The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Query!
Timepoint [11]
0
0
Baseline to Week 24
Query!
Secondary outcome [12]
0
0
Proportion of participants with a reduction in CDLQI =6 from baseline in participants with age =12 to <16 years old and with CDLQI baseline =6
Query!
Assessment method [12]
0
0
The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.
Query!
Timepoint [12]
0
0
Baseline to Week 24
Query!
Secondary outcome [13]
0
0
Change in Hospital Anxiety Depression Scale (HADS) from baseline
Query!
Assessment method [13]
0
0
The HADS is 14-item questionnaire with two subscales: anxiety & depression. Each subscale (anxiety & depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.
Query!
Timepoint [13]
0
0
Baseline to Week 24
Query!
Secondary outcome [14]
0
0
Proportion of participants with HADS subscale Anxiety (HADS-A) <8 in participants with baseline HADS-A =8
Query!
Assessment method [14]
0
0
HADS-A score ranges 0-21 with higher score indicating a poorer state.
Query!
Timepoint [14]
0
0
Baseline to Week 24
Query!
Secondary outcome [15]
0
0
Proportion of participants with HADS subscale Depression (HADS-D) <8 in participants with HADS-D baseline =8
Query!
Assessment method [15]
0
0
HADS-D score ranges 0-21 with higher score indicating a poorer state.
Query!
Timepoint [15]
0
0
Baseline to Week 24
Query!
Secondary outcome [16]
0
0
Absolute change in weekly average of daily Skin Pain-Numerical Rating Scale (SP-NRS) from baseline
Query!
Assessment method [16]
0
0
The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Query!
Timepoint [16]
0
0
Baseline to Week 24
Query!
Secondary outcome [17]
0
0
Proportion of participants with a reduction in weekly average of daily SP-NRS =4 from baseline in participants with baseline weekly average of daily SP-NRS =4
Query!
Assessment method [17]
0
0
The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.
Query!
Timepoint [17]
0
0
Baseline to Week 24
Query!
Secondary outcome [18]
0
0
Absolute change in weekly average of daily Sleep Disturbance-Numerical Rating Scale (SD-NRS) from baseline
Query!
Assessment method [18]
0
0
The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Query!
Timepoint [18]
0
0
Baseline to Week 24
Query!
Secondary outcome [19]
0
0
Proportion of participants with a reduction in weekly average of daily SD-NRS =3 from baseline in participants with Baseline weekly average of daily SD-NRS =3
Query!
Assessment method [19]
0
0
The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.
Query!
Timepoint [19]
0
0
Baseline to Week 24
Query!
Secondary outcome [20]
0
0
Percent change in EASI score from baseline
Query!
Assessment method [20]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
Query!
Timepoint [20]
0
0
Baseline to Week 24
Query!
Secondary outcome [21]
0
0
Percent change in weekly average of daily PP-NRS from baseline
Query!
Assessment method [21]
0
0
The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Query!
Timepoint [21]
0
0
Baseline to Week 24
Query!
Secondary outcome [22]
0
0
Absolute change in weekly average of daily PP-NRS from baseline
Query!
Assessment method [22]
0
0
The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.
Query!
Timepoint [22]
0
0
Baseline to Week 24
Query!
Secondary outcome [23]
0
0
Proportion of participants reaching EASI-50
Query!
Assessment method [23]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.
Query!
Timepoint [23]
0
0
Baseline to Week 24
Query!
Secondary outcome [24]
0
0
Proportion of participants with EASI =7
Query!
Assessment method [24]
0
0
The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.
Query!
Timepoint [24]
0
0
Baseline to Week 24
Query!
Secondary outcome [25]
0
0
Change in percent Body Surface Area (BSA) affected by AD from baseline
Query!
Assessment method [25]
0
0
Query!
Timepoint [25]
0
0
Baseline to Week 24
Query!
Secondary outcome [26]
0
0
Percent change in Scoring Atopic Dermatitis (SCORAD) index from baseline
Query!
Assessment method [26]
0
0
The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).
Query!
Timepoint [26]
0
0
Baseline to Week 24
Query!
Secondary outcome [27]
0
0
Absolute change in SCORAD index from baseline
Query!
Assessment method [27]
0
0
The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).
Query!
Timepoint [27]
0
0
Baseline to Week 24
Query!
Secondary outcome [28]
0
0
Proportion of participants with a reduction in SCORAD = 8.7 points from baseline in participants with baseline SCORAD score = 8.7
Query!
Assessment method [28]
0
0
The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).
Query!
Timepoint [28]
0
0
Baseline to Week 24
Query!
Secondary outcome [29]
0
0
Change in Patient Oriented Eczema Measure (POEM) from baseline
Query!
Assessment method [29]
0
0
The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.
Query!
Timepoint [29]
0
0
Baseline to Week 24
Query!
Secondary outcome [30]
0
0
Proportion of participants with a reduction in POEM =4 from baseline in participants with POEM Baseline =4
Query!
Assessment method [30]
0
0
The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.
Query!
Timepoint [30]
0
0
Baseline to Week 24
Query!
Secondary outcome [31]
0
0
Proportion of participants with rescue medication use
Query!
Assessment method [31]
0
0
Query!
Timepoint [31]
0
0
Baseline to Week 24
Query!
Secondary outcome [32]
0
0
Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs), experienced Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment-Emergent Adverse Events of Special Interest (AESI)
Query!
Assessment method [32]
0
0
Query!
Timepoint [32]
0
0
Baseline to Week 40
Query!
Secondary outcome [33]
0
0
Serum amlitelimab concentrations
Query!
Assessment method [33]
0
0
Query!
Timepoint [33]
0
0
Baseline to Week 40
Query!
Secondary outcome [34]
0
0
Incidence of antidrug antibodies (ADAs) of amlitelimab
Query!
Assessment method [34]
0
0
Query!
Timepoint [34]
0
0
Baseline to Week 40
Query!
Eligibility
Key inclusion criteria
- Participants must be 12 years of age (when signing informed consent form)
- Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology
Consensus Criteria)
- Documented history (within 6 months before screening) of either inadequate response or
inadvisability to topical treatments, and/or inadequate response to systemic therapies
(within 12 months before screening)
- v-IGA-AD of 3 or 4 at baseline visit
- EASI score of 16 or higher at baseline
- AD involvement of 10% or more of BSA at baseline
- Weekly average of daily PP-NRS of = 4 at baseline visit.
- Able and willing to comply with requested study visits and procedures
- Body weight =25 kg
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Skin co-morbidity that would adversely affect the ability to undertake AD assessments
- Known history of or suspected significant current immunosuppression
- Any malignancies or history of malignancies prior to baseline (with the exception of
non-melanoma skin cancer excised and cured >5 years prior to baseline)
- History of solid organ or stem cell transplant
- Any active or chronic infection including helminthic infection requiring systemic
treatment within 4 weeks prior to baseline (1 week in the event of superficial skin
infections)
- Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at
screening visit
- Having active tuberculosis (TB), latent TB, a history of incompletely treated TB,
suspected extrapulmonary TB infection, or who are at high risk of contracting TB
- Having received any of the specified therapy within the specified timeframe(s) prior
to the baseline visit
- In the Investigator's opinion, any clinically significant laboratory results or
protocol specified laboratory abnormalities at screening
- History of hypersensitivity or allergy to any of the excipients or investigational
medicinal product (IMP)
The above information is not intended to contain all considerations relevant to a potential
participation in a clinical trial
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/11/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/12/2025
Query!
Actual
Query!
Sample size
Target
420
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Investigational Site Number : 0360010 - Westmead
Query!
Recruitment hospital [2]
0
0
Investigational Site Number : 0360007 - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Investigational Site Number : 0360008 - East Melbourne
Query!
Recruitment hospital [4]
0
0
Investigational Site Number : 0360006 - Melbourne
Query!
Recruitment hospital [5]
0
0
Investigational Site Number : 0361006 - Traralgon West
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [5]
0
0
3844 - Traralgon West
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kentucky
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Mississippi
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oregon
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Utah
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Alberta
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
British Columbia
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Saskatchewan
Query!
Country [21]
0
0
Chile
Query!
State/province [21]
0
0
Reg Metropolitana De Santiago
Query!
Country [22]
0
0
Chile
Query!
State/province [22]
0
0
Valparaíso
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Beijing
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Chengdu
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Jinan
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Antony
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Paris
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Romans-sur-Isère
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Bad Bentheim
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Hamburg
Query!
Country [31]
0
0
Israel
Query!
State/province [31]
0
0
Haifa
Query!
Country [32]
0
0
Israel
Query!
State/province [32]
0
0
Jerusalem
Query!
Country [33]
0
0
Korea, Republic of
Query!
State/province [33]
0
0
Daegu-gwangyeoksi
Query!
Country [34]
0
0
Korea, Republic of
Query!
State/province [34]
0
0
Gyeonggi-do
Query!
Country [35]
0
0
Korea, Republic of
Query!
State/province [35]
0
0
Gyeongsangnam-do
Query!
Country [36]
0
0
Korea, Republic of
Query!
State/province [36]
0
0
Seoul-teukbyeolsi
Query!
Country [37]
0
0
Korea, Republic of
Query!
State/province [37]
0
0
Gwangju
Query!
Country [38]
0
0
Taiwan
Query!
State/province [38]
0
0
Taipei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind,
placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with
moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with
topical prescription therapies or when those therapies are not advisable.
The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab
solution for SC injection compared with placebo in participants with moderate to severe AD
aged 12 years and older.
Study details include:
At the end of the treatment period, participants will have an option to enter a separate
study: the blinded extension study EFC17600 (ESTUARY).
For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study
duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized
double-blind period, and a 16-week safety follow-up.
For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration
will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized
double-blind period.
The total treatment duration will be up to 24 weeks. The total number of visits will be up to
10 visits (or 9 visits for those entering the blinded extension study EFC17600] (ESTUARY).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06130566
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Trial Transparency email recommended (Toll free for US & Canada)
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
800-633-1610
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06130566
Download to PDF